Opioid analgesic effects on subjective well‐being in the operating theatre*
Open Access
- 28 June 2023
- journal article
- research article
- Published by Wiley in Anaesthesia
- Vol. 78 (9) , 1102-1111
Abstract
Summary: Exposure to opioid analgesics due to surgery increases the risk of new persistent opioid use. A mechanistic hypothesis for opioids' abuse liability rests on the belief that, in addition to pain relief, acute opioid treatment improves well‐being (e.g. via euphoria) and relieves anxiety. However, opioids do not consistently improve mood in laboratory studies of healthy non‐opioid users. This observational study determined how two commonly used opioid analgesics affected patients' subjective well‐being in standard clinical practice. Day surgery patients rated how good and how anxious they felt before and after an open‐label infusion of remifentanil (n = 159) or oxycodone (n = 110) in the operating theatre before general anaesthesia. One minute after drug injection, patients reported feeling intoxicated (> 6/10 points). Anxiety was reduced after opioids, but this anxiolytic effect was modest (remifentanil Cohen's d = 0.21; oxycodone d = 0.31). There was moderate to strong evidence against a concurrent improvement in well‐being (Bayes factors > 6). After remifentanil, ratings of ‘feeling good’ were significantly reduced from pre‐drug ratings (d = 0.28). After oxycodone, one in three participants felt better than pre‐drug. Exploratory ordered logistic regressions revealed a link between previous opioid exposure and opioid effects on well‐being, as only 14 of the 80 opioid‐naïve patients reported feeling better after opioid injection. The odds of improved well‐being ratings after opioids were higher in patients with previous opioid exposure and highest in patients with > 2 weeks previous opioid use (adjusted OR = 4.4). These data suggest that opioid‐induced improvement of well‐being is infrequent in opioid‐naïve patients. We speculate that peri‐operative exposure could increase risk of persistent use by rendering subsequent positive opioid effects on well‐being more likely.Keywords
Funding Information
- H2020 European Research Council (802885)
- Helse Sør-Øst RHF (2020087)
- National Institute on Drug Abuse (R01DA042033, R01DA048094)
This publication has 55 references indexed in Scilit:
- Markers of abuse liability of short- vs long-acting opioids in chronic pain patients: A randomized cross-over trialPharmacology Biochemistry and Behavior, 2009
- The prescription opioid, oxycodone, does not alter behavioral measures of impulsivity in healthy volunteersPharmacology Biochemistry and Behavior, 2009
- Evaluation of potential sex differences in the subjective and analgesic effects of morphine in normal, healthy volunteersPsychopharmacology, 2009
- Why do ineffective treatments seem helpful? A brief reviewChiropractic & Manual Therapies, 2009
- Within-subject comparison of the psychopharmacological profiles of oral oxycodone and oral morphine in non-drug-abusing volunteersPsychopharmacology, 2007
- Stress, Dysregulation of Drug Reward Pathways, and the Transition to Drug DependenceAmerican Journal of Psychiatry, 2007
- Placebos and painkillers: is mind as real as matter?Nature Reviews Neuroscience, 2005
- Pharmacokinetics of Oxycodone After Intravenous, Buccal, Intramuscular and Gastric Administration in ChildrenClinical Pharmacokinetics, 2004
- The Norwegian Brief Pain Inventory QuestionnaireJournal of Pain and Symptom Management, 2002
- Addiction Rare in Patients Treated with NarcoticsNew England Journal of Medicine, 1980